Yes, 30 million is absolute worst case scenario for dilution, which could only occur if the FDA needed a pivotal trial with 1000 patients or more and with the timeline for approval being extended well into 2027. I don't think that will happen but I always try to give the worst case scenario, which would IMO be $95 at FDA approval, and less dilution/shorter timelines would mean a higher share price.
Right now I believe we have 17.45 million shares fully diluted and, barring a buyout, I expect another raise of maybe $40-45 million AUD within the next 6 months or so, perhaps accompanied by an "IPO" on the Nasdaq.
Yes, 30 million is absolute worst case scenario for dilution,...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.20 |
Change
-0.200(1.30%) |
Mkt cap ! $321.3M | |||
| Open | High | Low | Value | Volume |
| $15.15 | $15.20 | $15.02 | $42.63K | 2.814K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4 | $15.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.20 | 243 | 1 |
View Market Depth
| Last trade - 10.35am 22/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |